PharmaTimes1d
Imfinzi receives NICE recommendation for lung cancer treatment
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
PharmaTimes1d
Poolbeg Pharma presents positive results for POLB 001
Poolbeg Pharma has unveiled encouraging pre-clinical study data for POLB 001 at the 66th American Society of Hematology (ASH) ...
PharmaTimes5d
Teva’s Ajovy shows positive results in preventing pediatric migraines
Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, demonstrating the efficacy and ...
PharmaTimes6d
Everest therapy shows promise in nephropathy trial
Everest Medicines has announced promising results from the Phase 1b/2a clinical trial of EVER001, a novel Bruton’s tyrosine ...
PharmaTimes5d
NICE endorses Neuraxpharm’s ublituximab for treating MS
Neuraxpharm Group has announced that the National Institute for Health and Care Excellence (NICE) has recommended ublituximab ...
PharmaTimes6d
Antag Therapeutics secures €80 million in weight loss therapy financing
Antag Therapeutics has announced the closing of an €80 million Series A financing round to develop AT-7687, a novel therapy targeting obesity. The round was led by Versant Ventures, with Novo Holdings ...